^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    DLL3 expression

    i
    Other names: DLL3, Delta Like Canonical Notch Ligand 3, Drosophila Delta Homolog 3, Delta-Like Protein 3, Delta3, Delta (Drosophila)-Like 3, Delta-Like 3 (Drosophila), Delta-Like 3, SCDO1
    Entrez ID:
    10683
    Related biomarkers:
    Expression
    2d
    DLL3 Expression in a Genotyped Cohort of Sporadic Medullary Thyroid Carcinomas. (PubMed, Am J Surg Pathol)
    Among cases with follow-up data (n=35), all 17 tumors with disease progression were DLL3 positive (13 RET-mutated tumors, 1 RAS-mutated tumor, and 3 RET/RAS wild-type tumors), including 5 with moderate expression and 12 with high expression. Most MTCs express DLL3; moreover, DLL3 expression is associated with lymph node metastases at diagnosis and disease progression, indicating that DLL3 may be an effective therapeutic target in MTC.
    Journal
    |
    RET (Ret Proto-Oncogene) • RAS (Rat Sarcoma Virus) • DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    RAS mutation • RET mutation • RAS wild-type • DLL3 expression • DLL3 positive
    8d
    A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3 (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Jun 2026 --> Sep 2027 | Trial primary completion date: May 2026 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    obrixtamig (BI 764532)
    19d
    Assessment of delta-like ligand 3 (DLL3) immunostaining in neuroendocrine tumors of the gynecological tract and comparing expression with other high-grade gynecological malignancies. (PubMed, Ann Diagn Pathol)
    In contrast, high-grade serous carcinomas lacked DLL3 expression. These findings demonstrate frequent DLL3 expression in gynecologic NETs and selected dedifferentiated malignancies, supporting DLL3 as a promising diagnostic marker and potential therapeutic target in gynecologic cancers.
    Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    25d
    DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy (clinicaltrials.gov)
    P3, N=390, Not yet recruiting, Boehringer Ingelheim | Trial completion date: May 2030 --> Dec 2029
    Trial completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    carboplatin • etoposide IV • obrixtamig (BI 764532)
    28d
    1438-0011: A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with standard chemotherapy. (2025-523869-22-00)
    P2/3, N=74, Not yet recruiting, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
    New P2/3 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    carboplatin • etoposide IV • obrixtamig (BI 764532)
    28d
    1438-0012: DAREON-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide treatment with standard chemotherapy. (2025-520565-51-00)
    P2/3, N=105, Not yet recruiting, Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
    New P2/3 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    VENTANA DLL3 (SP347) Assay
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • obrixtamig (BI 764532) • Actemra IV (tocilizumab)
    1m
    RAGNAR: Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab (clinicaltrials.gov)
    P2, N=87, Recruiting, Grupo Espanol de Tumores Neuroendocrinos
    Trial initiation date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    5-fluorouracil • irinotecan • leucovorin calcium • Imdelltra (tarlatamab-dlle)
    1m
    This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer. (clinicaltrials.gov)
    P1, N=55, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting | Initiation date: Nov 2025 --> Mar 2026
    Enrollment open • Trial initiation date • First-in-human
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    1m
    A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC (clinicaltrials.gov)
    P1, N=138, Recruiting, Shanghai Henlius Biotech | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    1m
    A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 (clinicaltrials.gov)
    P1, N=45, Active, not recruiting, Boehringer Ingelheim | Trial completion date: Jun 2026 --> Dec 2026
    Trial completion date
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    obrixtamig (BI 764532) • ezabenlimab (BI 754091)
    2ms
    A single‑arm, open‑label, dose‑finding clinical study to evaluate the safety and pharmacokinetic profile of SNC115 in patients with extensive‑stage small cell lung cancer (ES‑SCLC) (ChiCTR2600121014)
    P=N/A, N=30, Chinese Academy of Medical Sciences Cancer Hospital; National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Me
    New trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3) • CD70 (CD70 Molecule)
    |
    DLL3 expression
    2ms
    Multicenter, open-access Phase II clinical study of SHR-4849 injection combined with other anti-tumor drugs in patients with malignant solid tumors (ChiCTR2600117863)
    P2, N=120, Shandong Cancer Hospital; Suzhou Shengdiya Biomedical Co., LTD
    New P2 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    cisplatin • carboplatin • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)